Lung cancer

May 11, 2021

Thoracic radiotherapy at a dose of 60 Gy versus standard regimen for limited stage SCLC increases patient survival

Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions was so far considered the most effective regimen   In a phase II trial recently published in The Lancet Oncology, it was observed that the use of high-dose versus […]
April 28, 2021

New transcriptional subtype of small cell lung cancer has increased sensitivity to immunotherapy

Although the new standard of treatment for the extensive disease involves the integration of platinum, etoposide and immunotherapy considering the statistical gain in survival, this benefit is limited in unselected populations, emphasizing […]
April 27, 2021

Poziotinib administered twice a day improves tolerability in NSCLC treatment with EGFR exon 20 insertion mutations

Treatment for patients with metastatic non-small cell lung cancer (mNSCLC) with EGFR or HER2 exon 20 insertion mutations represents an important unmet need   The ZENITH20-5 trial (NCT03318939), presented at the American Association for Cancer Research (AACR) […]
April 26, 2021

Regular dose of osimertinib has limited activity in NSCLC with exon 20 insertion mutation

The exon 20 (ex20ins) insertion mutation is responsible for about 4 to 12% of the total EGFR gene mutations in patients with non-small cell lung cancer (NSCLC). These tumors are known to be less […]
April 22, 2021

Sintilimab is superior to docetaxel as a second-line treatment for advanced/metastatic SCC of the lung

Patients with advanced lung squamous cell carcinoma (SCC) have very limited second-line treatment options after platinum doublet treatment failure   ORIENT-3 (NCT03150875), a phase III, randomized, open-label and multicenter trial was presented in […]
October 21, 2020

Olaparib stands out as a treatment option in patients with castration-resistant metastatic prostate cancer

See the results of the PROfound trial presented at ESMO Virtual Congress 2020, whose updates of global survival data were published in the New England Journal […]
October 20, 2020

ESMO 2020: Impact of new studies in the treatment of lung cancer

Three main clinical trials for EGFR mutation non-small cell lung carcinoma presented at ESMO Virtual Congress 2020. FLAURA 2 The partial results of this trial that […]
August 31, 2020

New recommendation published on screening for lung cancer in people who do not show signs or symptoms

Such changes are expected to double the number of people in the United States eligible for computed tomography screening Smoking is the main risk factor for […]
August 7, 2020

Pyrotinib induces anti-tumor activity in non-small cell lung cancer with HER2 mutation

Non-small cell lung cancer (NSCLC) patients with HER2 mutation are between 1% and 4% of those diagnosed with lung adenocarcinoma A phase II, multicenter, open-label, single-arm […]